RoosterBio Inc. has joined the new NSF Engineering Research Center for Cell Manufacturing Technologies, known as CMaT. The center, launched in 2017 with a $20 million investment from the National Science Foundation, aims to revolutionize the treatment of cancer, heart disease, autoimmune diseases and other disorders by enabling scalable manufacturing and broad use of potentially curative therapies that utilize living cells – such as immune cells and stem cells – as “drugs.”